Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iteos Therapeutics Inc (NQ: ITOS )

14.44 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 14.44
Bid (Size) 5.810 (1)
Ask (Size) 22.00 (1)
Prev. Close 14.44
Today's Range 14.44 - 14.44
52wk Range 8.200 - 18.75
Shares Outstanding 35,763,742
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
From iTeos Therapeutics Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga

Performance

YTD
+24.59%
+24.59%
1 Month
-14.96%
-14.96%
3 Month
+13.88%
+13.88%
6 Month
+24.59%
+24.59%
1 Year
+8.08%
+8.08%

More News

Read More
ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Recap: ITeos Therapeutics Q4 Earnings
Via Benzinga
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday
Via Benzinga
Dow Jumps Over 100 Points; DNOW Posts Downbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Therapeutics Announces $120 Million Registered Direct Offering
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
From iTeos Therapeutics Inc.
Via GlobeNewswire
ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q4 2023
Via InvestorPlace
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos to Participate in Upcoming Investor Conferences
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Announces 2024 Strategic Priorities and Anticipated Milestones
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Wyndham Hotels & Resorts, Olink Holding And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Over $5M Bet On Asana? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
iTeos to Participate in Upcoming Investor Conferences
From iTeos Therapeutics Inc.
Via GlobeNewswire
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.